|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||26.00 - 28.35|
|52-week range||19.00 - 75.36|
|Beta (5Y monthly)||1.76|
|PE ratio (TTM)||N/A|
|Earnings date||14 Jun 2021 - 18 Jun 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
For us, stock picking is in large part the hunt for the truly magnificent stocks. Not every pick can be a winner, but...
China Resources will own 51% and DeepVerge will own 49% of the share capital MoU covers the manufacture, assembly and sale of environmental monitoring equipment DeepVerge PLC ("DeepVerge" or "the Company") YORK, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces that it has signed a non-binding Memorandum of Understanding ("MoU") with China Resources Environmental Protection Development Limited ("China Resources"), a wholly-owned subsidiary of China Resources Group, to enter into a Joint Venture ("JV") for the manufacture, assembly and sale of environmental monitoring equipment, with a view to future development of smart environmental platforms, equipment/devices and network management software capability. On or before closing, the parties will negotiate, agree, and execute a number of definitive agreements for the Joint Venture which are expected to be signed by 30 June 2021 with the JV becoming operational by 1 September 2021. DeepVerge would own 49% of the JV and China Resources 51%. The JV parties are currently undertaking a scoping exercise to assess the level of start-up costs and non-cash consideration to be introduced by each partner. The definitive agreements will address the following subject matters: The parties will agree and execute a commercial framework agreement which will incorporate commercial terms negotiated and agreed between the parties.DeepVerge will negotiate, agree and execute a licence by DeepVerge (or a subsidiary of DeepVerge) of technology to the JV and a support agreement in respect of the technology.JV will negotiate, agree and execute a reseller agreement with DeepVerge (or a subsidiary of DeepVerge) in respect of the manufactured products. Gerard Brandon CEO DeepVerge plc commented: "Today, the world needs big solutions to solve giant societal environmental problems. This joint venture is the most efficient route to deliver our world leading water technologies throughout the 23 provinces of China. A joint venture with a division of one of the world's largest natural resource groups can meet the growing demand for manufacturing and assembly of existing Microtox and Microtrace equipment for environmental monitoring across the rest of the world, that is struggling to manage a global health pandemic. By partnering with China Resources we can futureproof DeepVerge as a leading innovator of smart environmental platforms with AI, equipment/devices and network management software capability." Market Abuse Regulation (MAR) Disclosure THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. DeepVerge plcGerry Brandon+44 (0) 734 0055 648SPARK Advisory PartnersLimitedNeil Baldwin/Andrew Emmott+44 (0) 113 370 8974Turner Pope Investments (TPI) Limited (Broker)Andy Thacker / Zoe Alexander+44 (0) 20 3657 0050 Click on, or paste the following link into your web browser, to view the full announcement. http://www.rns-pdf.londonstockexchange.com/rns/8664W_1-2021-4-28.pdf This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.
Average virus breath condensate digital signal 9x larger than control on nano-chipYORK, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) -- DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces initial data for ongoing Phase III clinical studies on the detection of SARS-CoV-2 on breath samples and identification of confirmed COVID19 positive patients . Since Q3 2020, DeepVerge scientists have been working under laboratory conditions with the Spike Protein ("S-Protein") of SARS-CoV-2 on the SARS-CoV-2 virus inside the Containment Level 3 ("CL3") laboratories at the University of Aberdeen. In these studies, they have detected and identified the virus S-Protein in quantities at 40 femtogram[i] per millilitre ("Fg/mL") at close to 100% sensitivity and specificity on DeepVerge's Microtox® BT[ii] nano-optofluidic chip. In addition, under the clinical trial supervision of the Royal College of Surgeons, Ireland, 40 subjects, 16 of which were independently confirmed as COVID19 positive with PCR[iii] tests, provided breath samples that were tested on the Microtox® BT nano-optofluidic chip surface with Affimer® reagents ("Avacta Group")[iv] and Optimers ("Aptamer Group")[v] together the ("Binding Agents"). The breath samples detected binding on the nano-optofluidic chip with a secondary antibody to the Spike Protein which was initially selected for the isolated spike protein work. Detection of the live virus was confirmed indicating 9 times increase in the digital spectrum signal on the Microtox® BT when compared to controls of nano-optofluidic chips with binding agent; and 19 times increase in signal with nano-optofluidic chips without binding agents. Additional digital background noise was indicated due to the non-specific binding of the antibody. Further data is required to confirm the same high sensitivity and specificity is achieved on breath test clinical trials which are underway. Gerard Brandon CEO of DeepVerge plc commented:"DeepVerge scientists have transformed its AI based water contamination detection system, developed over five years for e.coli, into the breath condensate Microtox® BT unit. Having successfully completed Phase I testing on the Spike Protein and Phase II studies with SARS-CoV-2 virus in the safety of CL3 laboratories, the initial results of Phase III real-world clinical studies in COVID19 patients have reached a major milestone with the demonstration that our Microtox® BT can deliver results in under 60 seconds from breath samples. "The requirement for the UK Target Product Profile ("TPP") Rapid Breath Test requires 150 confirmed positive samples and 250 confirmed negative samples. Additional supervised breath test clinical trials from a larger group is expected to provide sufficient data to meet the desired and acceptable criteria in the TPP to roll out the COVID19 and other pathogen breath tests later this year." Please click on the PDF to view the full announcement http://www.rns-pdf.londonstockexchange.com/rns/6108S_1-2021-3-17.pdf Contacts DeepVerge plcGerard Brandon, CEO+44 (0) 7340 055 648 SPARK Advisory Partners Limited (Nominated Adviser)Neil Baldwin/Andrew Emmott+44 (0) 113 370 8974 Turner Pope Investments (TPI) Limited (Broker)Andy Thacker/Zoe Alexander+44 (0) 20 3657 0050